KRMD Overview

Introduction of Signals Xynthetica: Revvity, Inc. has launched Signals Xynthetica, an AI-augmented design platform aimed at enhancing molecular and materials discovery, integrating advanced design capabilities with experimental data in a Models-as-a-Service (MaaS) framework.

Addressing R&D Bottlenecks: The platform seeks to bridge the gap between computational models and experimental workflows, promoting a continuous learning loop that enhances predictive insights and aligns AI predictions with laboratory practices.

Strategic Evolution: Revvity is transitioning from providing standalone scientific tools to becoming a platform-centric technology partner, focusing on AI-driven insights and seamless integration of scientific data across various applications, including drug discovery and clinical laboratories.

Market Position and Future Prospects: While Revvity's stock performance has been modest compared to industry peers, the introduction of Signals Xynthetica and other AI initiatives positions the company for potential growth as demand for integrated predictive tools in scientific research increases.

510(k) Application Submission: KORU Medical Systems plans to submit a 510(k) application to the FDA for its FreedomEDGE Syringe Infusion System in late 2025 or early 2026, seeking clearance for use with a commercial oncology drug.

Infusion System Overview: The FreedomEDGE Infusion System is designed for large-volume subcutaneous drug delivery, proven with over 15 years of use, 45,000 patients, and 2 million annual infusions across more than 30 countries.

Multicenter Study Presentation: KORU Medical will present data from a multicenter study comparing the FreedomEDGE System to manual push techniques at the ESID/EHA/SIOPE Focused Symposium in November 2025, highlighting high satisfaction rates among nurses and patients.

Stock Performance: KRMD's stock has traded between $4.32 and $4.57 over the past year, closing at $4.49, reflecting a 3.94% increase in the latest trading session.

Upcoming Investor Conferences: KORU Medical Systems will participate in three investor conferences, including the Craig-Hallum Alpha Select Conference on November 18, 2025, the Canaccord Genuity MedTech Forum on November 20, 2025, and the Piper Sandler Healthcare Conference on December 2, 2025.

Product Overview: KORU Medical specializes in developing and commercializing patient-centric subcutaneous infusion solutions, including the Freedom Syringe Infusion System, which has been FDA cleared since 1994 and is designed for both home self-administration and use in ambulatory infusion centers.

Clinical Trials Support: The company also provides products for biopharmaceutical companies during clinical trials and can customize its infusion systems for various drug categories.

Investor Relations Contact: For more information, interested parties can visit KORU Medical's website or contact investor relations via email.